The 1,050 patients in the JAK inhibitor cohort, 41.5% of whom were male and 77.2% of whom were white, were an average of 61 years old, and 41.3% had Crohn's disease. The 9,124 patients in the TNF ...

IBD treatments evaluated were corticosteroids, aminosalicylates, immunomodulators (such as thiopurines and methotrexate), calcineurin inhibitors, biologics (such as monoclonal antibodies against ...

Despite the effectiveness of JAK inhibitors for IBD, the authors noted that concerns about cardiovascular safety have circulated since the 2022 ORAL Surveillance study found a higher risk of major ...